Key result
Radiotherapy was associated with an 18% increased risk of cardiovascular disease-related death compared to no radiotherapy in patients with lung and bronchus cancer (HR 1.18).
Why the study?
Radiation-related deaths from CVD are a concern in lung cancer, but few studies have examined CVD-related death associated with lung cancer.
Does radiotherapy increase the risk of cardiovascular disease-related death in patients with lung and bronchus cancer?
Cohort (n=225,570)
Yes
Does radiotherapy increase the risk of cardiovascular disease-related death in patients with lung and bronchus cancer?
Hazard Ratio: 1.18 (95% CI 1.13–1.23)
Absolute Event Rate: 48.4% vs 56.7%
p-value: p=<0.001
Radiotherapy in patients with lung and bronchus cancer is associated with a significantly increased long-term risk of cardiovascular-related death, highlighting the need for prolonged cardiovascular monitoring in this population.
May elevate CVD death risk after lung cancer radiotherapy; leaves open need for prospective trials before changing practice.
Background Radiotherapy plays an important role in the treatment of lung cancer. However, radiation-related deaths from cardiovascular disease (CVD) are a concern in these patients, and few studies have examined CVD-related death associated with lung cancer. We aimed to evaluate the risk of CVD-related death after radiotherapy in patients with lung and bronchus cancer. Methods Data were extracted from the surveillance, epidemiology, and end results database. Propensity score matching (PSM) was applied to reduce possible bias between patients who received radiotherapy and those who did not. The Kaplan–Meier method was used to estimate cardiovascular-specific survival (CVSS), and the log-rank test was used to compare CVSS between the radiotherapy and no radiotherapy groups. Cox proportional hazards regression analysis was performed to estimate the hazard ratio (HR) of CVD-related death. Results A total of 225,570 patients with lung and bronchus cancer were included, and 201,282 patients remained after PSM. Radiotherapy was identified as an independent risk factor for CVSS among patients with lung and bronchus cancer before PSM (HR: 1.18, P < 0.001) and after PSM (HR: 1.18, P < 0.001). Patients treated with radiotherapy had a significantly worse CVSS than those who did not receive radiotherapy before PSM (25-year CVSS: 49.9 vs. 56.4%, P = 0.002) and after PSM (25-year CVSS: 48.4 vs. 56.7%, P < 0.001). Radiotherapy was associated with more deaths from heart disease before PSM (81.9 vs. 77.2%, P < 0.001) and after PSM (83.0 vs. 78.7%, P < 0.001). Conclusion Radiotherapy is associated with an increased risk of CVD-related death, especially death from heart disease, in patients with lung and bronchus cancer. More efforts are needed to monitor cardiovascular health after radiotherapy.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2023) conducted a cohort in Lung and bronchus cancer (n=225,570). Radiotherapy vs. No radiotherapy was evaluated on Cardiovascular-specific survival (CVSS) (HR 1.18, 95% CI 1.13-1.23, p=<0.001). Radiotherapy was associated with an 18% increased risk of cardiovascular disease-related death compared to no radiotherapy in patients with lung and bronchus cancer (HR 1.18).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: